EGFR and inflammatory breast carcinoma: One exception to the low pCR rates observed in TN-IBC was seen in a single arm study that evaluated the addition of panitumumab, an anti-EGFR antibody to standard chemotherapy and reported a pCR rate of 42% (8 of 19) patients [31].